Gülin ÖZDAMAR ÜNAL, Kadriye Ece DEMİRAY, Onur ÜNAL

Do patients with major depressive disorder and generalized anxiety disorder experience more somatosensorial amplification, hypochondriasis, and fear of COVID-19?

Objective: Mental illnesses are important determinants in response to the pandemic. However, there are only a limited number of studies investigating the effects of COVID-19 in individuals with mental illnesses. We aimed to reveal the fear of COVID-19, somatosensorial amplification levels, anxiety, depression, and stress levels of patients with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Method: We evaluated 500 participants in three groups. This study enrolled 137 patients with MDD, 140 patients with GAD, and 223 healthy controls. Participants were evaluated with the Whiteley Index-7, Somatosensory Amplification Scale (SSAS), Depression Anxiety Stress Scale-21 (DASS-21), and The Fear of COVID-19 Scale. Results: There was a statistically significant difference between the groups’ SSAS, DASS-21, Whiteley Index, and The Fear of COVID-19 Scale scores. In the post hoc analysis, Whiteley Index and DASS-21 subscale scores were higher in patient groups than in the control group (p

PDF

___

1. Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, et al. The 2019-2020 novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic: A joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis 2020; 12:47-93.
2. Marcinko D, Jakovljevic M, Jaksic N, Bjedov S, Mindoljevic Drakulic A. The importance of psychodynamic approach during COVID-19 pandemic. Psychiatr Danub 2020; 32:15-21.
3. Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis. Psychiatry Res 2020; 291:113190.
4. Pan KY, Kok AAL, Eikelenboom M, Horsfall M, Jorg F, Luteijn RA, et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry 2020; 8:121- 129.
5. Quittkat HL, Dusing R, Holtmann FJ, Buhlmann U, Svaldi J, Vocks S. Perceived impact of Covid-19 across different mental disorders: A study on disorder-specific symptoms, psychosocial stress and behavior. Front Psychol 2020; 11:586246.
6. Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, et al. Do psychiatric patients experience more psychiatric symptoms during COVID- 19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun 2020; 87:100-106.
7. Kovács Z, D’Agostino DP, Diamond D, Kindy MS, Rogers C, Ari C. Therapeutic potential of exogenous ketone supplement induced ketosis in the treatment of psychiatric disorders: Review of current literature. Front Psychiatry 2019; 10:1-15.
8. Cooke JE, Eirich R, Racine N, Madigan S. Prevalence of posttraumatic and general psychological stress during COVID- 19: A rapid review and meta-analysis. Psychiatry Res 2020; 292:113347.
9. Wielgus B, Urban W, Patriak A, Cichocki L. Examining the associations between psychological flexibility, mindfulness, psychosomatic functioning, and anxiety during the COVID- 19 pandemic: A path analysis. Int J Env Res Public Heal 2020; 17:8764.
10. Gonzalez-Blanco L, Dal Santo F, Garcia-Alvarez L, de la Fuente- Tomas L, Moya Lacasa C, Paniagua G, et al. COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls? Schizophr Res 2020; 223:192-198.
11. Pilowsky I. Dimensions of hypochondriasis. Br J Psychiatry 1967; 113:89-93.
12. Fink P, Ewald H, Jensen J, Sorensen L, Engberg M, Holm M, et al. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. J Psychosom Res 1999; 46:261-273.
13. Gulec H, Yazıcı Gulec M, Keles Ünal E, Karabekiroglu A, Sayar K, Kose S. Turkish version of the Whiteley Index (Turkish WI-7): Reliability, validity,and factorial structure. Turk J Clin Psychiatry 2013; 16:27-33.
14. Berens S, Banzhaf P, Baumeister D, Gauss A, Eich W, Schaefert R, et al. Relationship between adverse childhood experiences and illness anxiety in irritable bowel syndrome - The impact of gender. J Psychosom Res 2020; 128:109846.
15. Barsky AJ, Wyshak G, Klerman GL. The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatr 1990; 24:323-334.
16. Güleç H, Sayar K. Reliability and validity of the Turkish form of the Somatosensory Amplification Scale. Psychiatry Clin Neurosci 2007; 61:25-30.
17. Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995; 33:335-343.
18. Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales. Second ed., Sydney, Australia: Psychology Foundation, 1995,
19. Sarıçam. H. The psychometric properties of Turkish version of Depression Anxiety Stress Scale-21 (DASS-21) in health control and clinical samples. J Cogn Psychother Res 2018; 7:19-30.
20. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The fear of COVID-19 Scale: Development and initial validation. Int J Ment Heal Addict 2020;1-9. doi: 10.1007/s11469- 020-00270-8. Online ahead of print.
21. Bakioglu F, Korkmaz O, Ercan H. Fear of COVID-19 and positivity: Mediating Role of intolerance of uncertainty, depression, anxiety, and stress. Int J Ment Health Addict 2021; 19:2369-2382
22. Spinhoven P, Van Der Does AJW. Somatization and somatosensory amplification in psychiatric outpatients: an explorative study. Compr Psychiatry 1997; 38:93-97.
23. Kumar V, Avasthi A, Grover S. Somatosensory amplification, health anxiety, and alexithymia in generalized anxiety disorder. Ind Psychiatry J 2018; 27:47-52.
24. Taycan O, Ozdemir A, Erdogan-Taycan S, Jurcik T. Associations of somatic symptom attribution in Turkish patients with major depression. Nord J Psychiatry 2015; 69:167-173.
25. Simon GE, VonKorff M. Somatization and psychiatric disorder in the NIMH epidemiologic catchment area study. Am J Psychiatry 1991; 148:1494-1500.
26. Escobar JI, Cook B, Chen CN, Gara MA, Alegría M, Interian A, et al. Whether medically unexplained or not, three or more concurrent somatic symptoms predict psychopathology and service use in community populations. J Psychosom Res 2010; 69:1-8.
27. Kohlmann S, Gierk B, Hilbert A, Brähler E, Löwe B. The overlap of somatic, anxious and depressive syndromes: A population-based analysis. J Psychosom Res 2016 [cited 2021; 90:51-56.
28. Sayar K, Kirmayer LJ, Taillefer SS. Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry 2003; 25:108-114.
29. Goodwin R, Gaines SO, Myers L, Neto F. Initial psychological responses to swine flu. Int J Behav Med 2011; 18:88-92.
30. Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord 2020; 277:55- 64.